News & Events
News
-
18Jun. 2018Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
CAMBRIDGE, Mass., June 18, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that preliminary data from an ongoing phase I study from the nicotinamide-based natural killer cell expansion, or NAM-NK, program will be presented during the Inaugural AACR International Meeting on Advances in Malignant Lymphoma, held June 22 – 26 […]
-
30Apr. 2018Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting
CAMBRIDGE, Mass., April 30, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that data from the company’s NiCord program will be presented during the International Society for Cellular Therapy (ISCT) Annual Meeting, held May 2-5 in Montreal. Jaap Jan Boelens, M.D., Ph.D., clinical study investigator and pediatric oncologist/immunologist at the […]
-
26Apr. 2018Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
CAMBRIDGE, Mass., April 26, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointments of Josh Hamermesh as chief business officer and Paul Nee as vice president, marketing. Mr. Hamermesh will lead the business operations and corporate development strategies for the company. Mr. Hamermesh joins Gamida Cell from Locust Walk […]
-
19Mar. 2018Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting
NiCord recipients demonstrated rapid and robust immune reconstitution following transplantation CAMBRIDGE, Mass., March 19, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that new data on immune reconstitution (IR) from its phase I/II study of NiCord in high-risk hematologic malignancies will be presented during the 44th Annual Meeting of the […]
-
16Mar. 2018Gamida Cell to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that the company will participate in two upcoming investor conferences: Julian Adams, Ph.D., chairman and chief executive officer, will share a company overview at the Oppenheimer 28th Annual Healthcare Conference at 2:45 p.m. on Wednesday, March 21, 2018 […]
-
15Mar. 2018Gamida Cell Appoints Shai Lankry as Chief Financial Officer
CAMBRIDGE, Mass., March 15, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Shai Lankry, CPA, MBA, as chief financial officer (CFO). Mr. Lankry brings more than a decade of senior management experience in finance at both public and private companies to his new role as CFO of […]
-
20Feb. 2018Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
– NiCord demonstrated rapid and durable engraftment in patients with high-risk hematologic malignancies – – 13 patients with sickle cell disease transplanted with NiCord and engrafted at median seven days – CAMBRIDGE, Mass., February 20, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced two presentations from its NiCord programs in […]
-
16Jan. 2018Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
CAMBRIDGE, Mass., January 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma. “There is significant need for novel therapeutic approaches for […]
-
11Dec. 2017Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting
— Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers — — Preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer — JERUSALEM and CAMBRIDGE, Mass., December 11, 2017 – Gamida Cell, a leading cellular […]
-
20Nov. 2017Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer
Biotech leader to further advance promising pipeline, including breakthrough therapy, NiCord®, in phase 3 development as a universal bone marrow transplant solution JERUSALEM, Israel and CAMBRIDGE, Mass., November 20, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer. Dr. […]
-
1Nov. 2017Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting
Phase 2 NiCord Data in Allogeneic Bone Marrow Transplant and Preclinical Data for NK Cells to be Presented in Oral Presentations JERUSALEM, Israel, November 1, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that two oral presentations on new data from the company’s pipeline programs will be presented during the […]
-
26Sep. 2017Gamida Cell World Cord Blood Day Conference, November 15, 2017
Advisory Event: Gamida Cell World Cord Blood Day Conference This conference will present the newest research in cord blood expansion for cellular and immune treatment of cancer and orphan genetic diseases. Date: November 15, 2017 Location: Gamida Cell, Beit Ofer, 5 Nahum Hafzadi Street, Jerusalem, ISRAEL. This event is open to the general public. Contact: kelly@gamida-cell.com […]
-
21Aug. 2017Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI) Jerusalem, Israel, August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. […]
-
20Jul. 2017Gamida Cell Announces $3.5 Million Grant from the Israeli Government
Non-dilutive funding follows the recent closing of a $40 million round Combined financing will support further development and commercialization of NiCord®, a breakthrough designation product for blood cancers Jerusalem, Israel, July 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that […]
-
10Jul. 2017Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join […]
-
19Jun. 2017Gamida Cell Announces $40 Million Private Financing
Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers Jerusalem, Israel, June 19, 2017 — Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the signing of a $40 million financing to […]
-
5Jun. 2017Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors
Professor Kornberg brings to Gamida Cell a celebrated expertise in scientific discovery and therapeutic development Dr. Perry brings deep R&D expertise in cell and gene therapy and decades of experience successfully guiding private and publicly traded companies Jerusalem, Israel, June 5, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment […]
-
20Apr. 2017Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation
NiCord-transplanted patients demonstrated improvements in time to engraftment, bacterial and non-viral grade 2-3 infection rate, and duration of hospitalization Jerusalem, Israel, April 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today the publication of positive clinical outcomes from an investigator-initiated study […]
-
23Mar. 2017Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)
Phase 3 study of NiCord commenced last month in blood cancer patients Jerusalem, Israel, March 23, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that orphan drug designation has been granted by the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal […]
-
28Feb. 2017Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers
Jerusalem, Israel, February 28, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the first patient has been transplanted in the Company’s Phase 3 study of NiCord®, in development as a cure for patients with blood cancer who do not have […]
-
6Dec. 2016Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016
SCD patients treated with NiCord showed rapid engraftment and were cured of disease symptoms
-
21Nov. 2016Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board
Jerusalem, Israel, November 21, 2016 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the appointment of Julian Adams, Ph.D. as the Company’s new chairman of the Board of Directors. “I am very pleased to welcome Julian Adams as our new chairman after […]
-
11Oct. 2016Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®
NiCord is a novel graft modality for bone marrow transplantation in patients with hematological malignancies including leukemia and lymphoma
-
15Sep. 2016Gamida Cell Announces Appointment of Julian Adams, Ph.D.and Kenneth I. Moch to its Board of Directors
New directors bring extensive experience in building and overseeing corporate strategy of growing life sciences companies to Board
-
27Jul. 2016Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source
CordIn has the potential to be a sole graft source for rare genetic diseases where transplantation is the only clinically established cure
-
6Jun. 2016Gamida Cell Presents Data From Phase 1/2 Study of NiCord® for High Risk Hematological Malignancies at ASCO 2016
Patients treated with NiCord showed improved engraftment, reduced morbidity and less transplant related mortality compared to controls
-
23May. 2016Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Non-dilutive funding will support further development of NiCord® for blood cancers, CordIn® for rare genetic diseases and NK cells for immune therapy of cancer
-
5Apr. 2016Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients at EBMT 2016
Data demonstrate rapid engraftment, reduced bacteria infections and shortened hospitalization
-
7Nov. 2015Gamida Cell Reports Positive Top Line Results of International, Multi-Center, Phase I/II Study of NiCord® for Blood Cancers, Demonstrating Rapid and Durable Hematopoietic Recovery
Positive results support the initiation of a Phase III study of NiCord Jerusalem, Israel, December 7, 2015 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today positive top line results from the Phase I/II study of NiCord, in development as an experimental treatment […]
-
12Oct. 2015Gamida Cell Announces Strategic Equity Investment by Major Pharmaceutical Company
To support continued clinical development of NiCord®for blood cancers Jerusalem, Israel, October 12, 2015 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Novartis will invest up to an additional $15 million in the Company in current and future equity. The investment […]
-
15Aug. 2015Gamida Cell Achieves Major Regulatory Milestone: FDA and EMA Respond Positively to NiCord® Phase III Study Design Outline
Gamida Cell plans to commence Phase III study of NiCord in 2016 Jerusalem, Israel, August 10, 2015 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design […]
-
8Jan. 2015First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell’s Ongoing Phase I/II Clinical Trial for Blood Cancers
This is the first transplantation to use a graft of ex-vivo expanded, cryopreserved, cord blood progenitor cells Jerusalem, Israel, January 8, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that the first person has been successfully transplanted with cryopreserved (frozen) NiCord® in the […]
-
6Jan. 2015Gamida Cell’s NiCord® Receives FDA and EMA Orphan Drug Designation
NiCord® is in clinical development as a treatment for blood cancers including leukemia and lymphoma Jerusalem, Israel, January 6, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, […]
-
19Aug. 2014Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Jerusalem, Israel, August 19, 2014 — Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG (“Novartis”). According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and […]
-
9Sep. 2013Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration
We are witnessing a paradigm shift in transplantation. The first patient was successfully transplanted with a stem cell graft entirely expanded in ex vivo cultures and without the support of a second unit of un-manipulated stem cells. Gamida Cell CEO Dr. Yael Margolin Jerusalem, Israel, September 9, 2013 — Gamida Cell announced today that the […]
-
14Feb. 2013Gamida Cell’s NiCord® Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study
Study results presented in an Oral Presentation at the 2013 BMT Tandem Meetings in Salt Lake City, Utah Jerusalem, Israel, February 14, 2013 — Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company’s proprietary NAM technology. Study […]
-
12Nov. 2012First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University
Jerusalem, Israel, November 12, 2012 — Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord® as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke […]
-
19Sep. 2012Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® For Hematological Malignancies
Gamida Cell’s flagship product StemEx® remains on course: Phase III study results in Q4/12 Jerusalem, Israel, September 19, 2012 — Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product. NiCord is in […]